NASDAQ:VICL - Vical Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.26 +0.02 (+1.61 %)
(As of 06/21/2018 12:25 PM ET)
Previous Close$1.26
Today's Range$1.26 - $1.26
52-Week Range$1.02 - $3.70
Volume302 shs
Average Volume364,432 shs
Market Capitalization$28.36 million
P/E Ratio-1.27
Dividend YieldN/A
Vical logoVical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. It is developing various DNA-based vaccines and other therapeutics, such as VCL-HB01 therapeutic vaccine for herpes simplex virus-2 that is in Phase II clinical trial to prevent and protect against lesion recurrence; VL-2397 antifungal program, which is in Phase I clinical trial for the treatment of invasive fungal infections; and CyMVectin prophylactic vaccine for CMV that is in preclinical stage for the prevention of fetal transmission during pregnancy. The company also engages in contract manufacturing of plasmid investigational products for various clients. It has collaborations with Astellas to develop and commercialize certain products, including ASP0113 for the control and prevention of CMV infection in immunocompromised patients; and Merial for use of the company's core DNA delivery technology in a therapeutic vaccine designed to aid in extending survival time of dogs with oral melanoma. It also has a license agreement with Astellas to develop and commercialize novel antifungal candidate. The company was founded in 1987 and is headquartered in San Diego, California.

Receive VICL News and Ratings via Email

Sign-up to receive the latest news and ratings for VICL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic


Debt-to-Equity RatioN/A
Current Ratio18.27
Quick Ratio18.27


Trailing P/E Ratio-1.27
Forward P/E Ratio-1.17
P/E GrowthN/A

Sales & Book Value

Annual Sales$13.82 million
Price / Sales1.99
Cash FlowN/A
Price / CashN/A
Book Value$3.42 per share
Price / Book0.37


EPS (Most Recent Fiscal Year)($1.01)
Net Income$-12,960,000.00
Net Margins-144.80%
Return on Equity-32.93%
Return on Assets-27.09%


Outstanding Shares21,820,000

Vical (NASDAQ:VICL) Frequently Asked Questions

What is Vical's stock symbol?

Vical trades on the NASDAQ under the ticker symbol "VICL."

How were Vical's earnings last quarter?

Vical Incorporated (NASDAQ:VICL) issued its earnings results on Thursday, May, 3rd. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by $0.12. The biotechnology company earned $0.72 million during the quarter, compared to the consensus estimate of $2.10 million. Vical had a negative return on equity of 32.93% and a negative net margin of 144.80%. View Vical's Earnings History.

When is Vical's next earnings date?

Vical is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Vical.

What price target have analysts set for VICL?

2 Wall Street analysts have issued 1-year target prices for Vical's shares. Their predictions range from $3.50 to $3.50. On average, they anticipate Vical's stock price to reach $3.50 in the next twelve months. View Analyst Ratings for Vical.

Who are some of Vical's key competitors?

Who are Vical's key executives?

Vical's management team includes the folowing people:
  • Mr. Vijay B. Samant, Chief Exec. Officer, Pres and Director (Age 65)
  • Mr. Anthony Alan Ramos, Chief Financial Officer & Principal Accounting Officer (Age 51)
  • Dr. Lawrence Russell Smith Ph.D., Sr. VP of Research (Age 57)
  • Mr. Keith D. Hall M.D., VP of Operations (Age 56)
  • Dr. Mammen P. Mammen Jr., M.D., Sr. VP of Clinical Devel. (Age 54)

Has Vical been receiving favorable news coverage?

Media headlines about VICL stock have trended somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Vical earned a news sentiment score of 0.10 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 47.05 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Vical?

Shares of VICL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vical's stock price today?

One share of VICL stock can currently be purchased for approximately $1.26.

How big of a company is Vical?

Vical has a market capitalization of $28.36 million and generates $13.82 million in revenue each year. The biotechnology company earns $-12,960,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. Vical employs 74 workers across the globe.

How can I contact Vical?

Vical's mailing address is 10390 PACIFIC CENTER COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-646-1100 or via email at [email protected]

MarketBeat Community Rating for Vical (VICL)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  161 (Vote Outperform)
Underperform Votes:  108 (Vote Underperform)
Total Votes:  269
MarketBeat's community ratings are surveys of what our community members think about Vical and other stocks. Vote "Outperform" if you believe VICL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VICL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/21/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.